Company intelligence / Profile preview

New Medicine

Tel Aviv, Israel

Ownership: Private
Development stage: Other

Overview

New Medicine (NewMed) is a clinical-stage biotechnology company that utilizes advanced mathematical modeling and simulation to optimize drug development and personalized treatment regimens. Founded by Professor Zvia Agur, the company focuses on oncology, using its proprietary platform to predict drug efficacy and toxicity in individual patients. By integrating biological data with mathematical algorithms, New Medicine aims to improve the success rate of clinical trials and provide more effective, tailored therapies for various solid tumors. The company's approach bridges the gap between theoretical biology and clinical application, offering a unique methodology for dose optimization and combination therapy design.

Therapeutic areas: Oncology
Modalities: Small moleculeMathematical modeling
Industry: Biotech

Partnerships

Optimata

Beyond the preview

Go deeper on New Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Medicine.

Explore the full profile